Cargando…
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
BACKGROUND: PARP inhibitors, such as Olaparib, have advanced the treatment of ovarian cancer by providing patients with an effective and molecularly-targeted maintenance therapy. However, all orally-administered drugs, including Olaparib, must undergo first-pass metabolism. In contrast, a nanopartic...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278886/ https://www.ncbi.nlm.nih.gov/pubmed/30555227 http://dx.doi.org/10.2147/IJN.S186881 |